The generic drug Sofosbuvir for treating chronic Hepatitis C in India is soon to be launched under the brand name 'Hepcvir'.
"Sofusbuvir marks a new era of medicines in oral treatment of Hepatitis C which reduce the need for injectables," Cipla Chief Medical Officer Jaideep Gogtay said.
Hepatitis C
Hepatitis C is a contagious viral disease affecting the liver that is caused by the hepatitis C virus.
Advertisement
Cipla has signed a licensing agreement with Gilead to manufacture the drug Sofosbuvir and it will be made available to Indian patients in a week's time.
"Cipla has always brought accessible and affordable medicines to fight against diseases like AIDS and Hepatitis B; hence, Cipla has made it a priority to bring Hepcvir to patients in India as well as the other developing nations," Cipla MD & Global CEO Subhanu Saxena said.
Dr Reddy's entered into an agreement with Hetero to distribute and market generic version of US-firm Gilead Sciences' Hepatitis C drug under the brand 'Resof' in India.
Source: Medindia
Dr Reddy's entered into an agreement with Hetero to distribute and market generic version of US-firm Gilead Sciences' Hepatitis C drug under the brand 'Resof' in India.
Source: Medindia
New Treatments for Hepatitis C
Until very recently, infection with the Hepatitis C Virus (HCV) had been very difficult to treat, but new treatments now result in curing the disease in up to 90% of cases.
Advertisement
New Drug, Sofosbuvir, Found Very Efficient in Treating Chronic Hepatitis C Virus InfectionA new drug, Sofosbuvir, has been found very efficient in treating different types of chronic Hepatitis C Virus infection; it is in the third phase of clinical trials. | Advertisement
|
Advertisement
Recommended Readings
Latest Drug News
The psychedelic market set for remarkable growth, projected to hit $7.2B by 2029 with a strong 55% CAGR.
The study explores whether CDNF could influence the progression of ALS in rodent models and to elucidate the mechanism through which it operates.
Amoxicillin-clavulanate use in acute sinusitis patients is associated with a higher incidence of adverse events.
Professionals advocate for enhanced education of patients and caregivers, and creation of more effective child-resistant systems for monitoring ADHD medication.
In June, WHO raised concerns about 7 Indian cough syrups after complaints from several countries about contamination and health issues.
